New Retina Radio by Eyetube Eyetube

David RP Almeida, MD, PhD, MBA; Lisa Faia, MD; and Chris Riemann, MD, return for the second episode in this podcast miniseries, in which they review a trio of real-world GA cases, explore what early responses to treatment look like, and ask how to address GA in the presence of wet AMD. 

Join David RP Almeida, MD, PhD, MBA; Lisa Faia, MD; and Chris Riemann, MD, as they assess which clinical and non-clinical characteristics drive their decision-making in patients with geographic atrophy (GA). After the break, Dr. Faia shares a real-world case from her clinic in which a patient who was lost to follow-up returns to consider treatment.

What conclusions can be drawn from a cross-trial comparison of randomized clinical trials assessing the safety and efficacy of anti-VEGF agents used in the treatment of AMD and DME? Paul Hahn, MD, PhD, sits down with Durga Borkar, MD, MMCi, and Ted Leng, MD, to review a recent presentation by Dr. Leng on this topic, and to examine the clinical relevance of the study's findings. 

Biosimilars in retina are here. How are practices integrating them into their clinics? And how do they navigate issues around payer policy, protocol changes, and ensuring continuity of care? 

Moderator John Kitchens, MD, sits down with retina specialist Dave Brown, MD, and Kristin Yockus, the VP of Process Integrations at Retina Consultants of America, to answer these questions, and to preview how the coming increase in biosimilar options might play out in a real-world landscape. 

How do endophthalmitis rates after intravitreal injection differ after using povidone-iodine compared with chlorhexidine? Moderator Sruthi Arepalli, MD, hears from panelists Vaidehi Dedania, MD, and Rebecca Soares, MD, MPH, about a recent peer-reviewed retrospective cohort study on this topic. After the break, the trio discuss how to manage patients who do not tolerate antiseptics, the benefits of visualizing antiseptics on the conjunctiva, and the specific practice patterns that work best in their clinics. 

Performing surgery for symptomatic vitreous opacities (SVO) was once verboten in retina medicine, but the field has seen a sea-change in mindset over the past decade. In this podcast, moderator John Kitchens, MD, is joined by Edwin H. Ryan, MD; Christina Y. Weng, MD, MBA; and Alison Bozung, OD, to explore why surgery for SVO has become more palatable and how this evolution in mindset is impacting patients' quality of life.